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Definition and clinical picture: We propose the minimal definition of Dercum’s disease to be generalised
overweight or obesity in combination with painful adipose tissue. The associated symptoms in Dercum’s disease
include fatty deposits, easy bruisability, sleep disturbances, impaired memory, depression, difficulty concentrating,
anxiety, rapid heartbeat, shortness of breath, diabetes, bloating, constipation, fatigue, weakness and joint aches.
Classification: We suggest that Dercum’s disease is classified into: I. Generalised diffuse form A form with diffusely
widespread painful adipose tissue without clear lipomas, II. Generalised nodular form - a form with general pain in
adipose tissue and intense pain in and around multiple lipomas, and III. Localised nodular form - a form with pain in
and around multiple lipomas IV. Juxtaarticular form - a form with solitary deposits of excess fat for example at the
medial aspect of the knee.
Epidemiology: Dercum’s disease most commonly appears between the ages of 35 and 50 years and is five to
thirty times more common in women than in men. The prevalence of Dercum’s disease has not yet been exactly
established.
Aetiology: Proposed, but unconfirmed aetiologies include: nervous system dysfunction, mechanical pressure on
nerves, adipose tissue dysfunction and trauma.
Diagnosis and diagnostic methods: Diagnosis is based on clinical criteria and should be made by systematic
physical examination and thorough exclusion of differential diagnoses. Advisably, the diagnosis should be made by
a physician with a broad experience of patients with painful conditions and knowledge of family medicine, internal
medicine or pain management. The diagnosis should only be made when the differential diagnoses have been
excluded.
Differential diagnosis: Differential diagnoses include: fibromyalgia, lipoedema, panniculitis, endocrine disorders,
primary psychiatric disorders, multiple symmetric lipomatosis, familial multiple lipomatosis, and adipose tissue
tumours.
Genetic counselling: The majority of the cases of Dercum’s disease occur sporadically. A to G mutation at position
A8344 of mitochondrial DNA cannot be detected in patients with Dercum’s disease. HLA (human leukocyte
antigen) typing has not revealed any correlation between typical antigens and the presence of the condition.* Correspondence: emma.hansson@med.lu.se
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http://www.ojrd.com/content/7/1/23Management and treatment: The following treatments have lead to some pain reduction in patients with
Dercum’s disease: Liposuction, analgesics, lidocaine, methotrexate and infliximab, interferon α-2b, corticosteroids,
calcium-channel modulators and rapid cycling hypobaric pressure. As none of the treatments have led to long
lasting complete pain reduction and revolutionary results, we propose that Dercum’s disease should be treated in
multidisciplinary teams specialised in chronic pain.
Prognosis: The pain in Dercum’s disease seems to be relatively constant over time.
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Dercum’s disease is a rare disease listed by Orphanet [1]
and by the National Organization for Rare Disorders
(NORD) [2]. It is characterised by generalised over-
weight or obesity, pronounced pain in the adipose tissue
and a number of associated symptoms. The pain is
chronic (>3 months), symmetrical, often disabling [3]
and is resistant to traditional analgesics [4]. The aim of
this review was to describe the classification, symptoms
and diagnosis of the disease as well as the epidemiology,
aetiology, genetic counselling, treatment and prognosis
of it.
Disease name/synonyms
Synonyms of the disease that can be found in the med-
ical literature include Dercum’s disease, Morbus Der-
cum, adiposis dolorosa, adiposalgia, lipomatosis dolorosa
and adipose tissue rheumatism [5].
Definition and clinical description
The main symptoms of Dercum’s disease, according to
the early reports, are obesity and painful adipose tissue
[6]. The most common locations for painful fat and for
lipomas are the extremities, the trunk, the pelvic area,
and the buttocks (Figure 1). When palpable lipomas
exist they vary in size and firmness [7]. The pain is most
commonly described by the patients as burning or ach-
ing. It can vary from hyperalgesia in the subcutaneous
fatty tissue [4] and discomfort on palpation to paroxys-
mal spontaneous attacks of pain. Based on a question-
naire including 110 individuals with Dercum’s disease
Herbst and Asare-Bediako found that the most common
locations for painful fat and for lipomas are the extrem-
ities, the trunk, the pelvic area, and the buttocks [7] Fig-
ure 2. Our experience of pain distribution based on
clinical examination of more than 100 patients is
depicted in Figure 1 and 3 where the most painful areas
are shown. In more general terms upper arms, abdomen,
buttocks and thighs are the most common areas. For ex-
ample, in the upper arm patients have more pain in the
medial aspect of the extremity. In the thigh more pain is
found medially and laterally than anteriorly and poster-
iorly. The onset of the condition may be abrupt or indo-
lent [7].In 1901, Roux and Vitaut [8] proposed four cardinal
symptoms of Dercum’s disease:
1. Multiple, painful, fatty masses
2. Generalised obesity
3. Weakness and susceptibility to fatigue (asthenia)
4. Psychiatric manifestations, including emotional
instability, depression, epilepsy, confusion, and
dementia.
However, it can be discussed which symptoms are car-
dinal and which are associated. In fact, already in 1927,
Labbé and Boulin [9] questioned whether the weakness
and susceptibility to fatigue and psychiatric manifesta-
tions should be classified as cardinal symptoms. They
argued that obesity per se can induce asthenia, and that
it is unclear whether mental disturbances should be
included as a cardinal symptom, as they have not been
described in all cases of Dercum’s disease [9]. Moreover,
in 1910, Stern [10] remarked that the only two symp-
toms that are always present in the disease are obesity
and painful adipose tissue. Furthermore, in 1930, Gram
presented 69 cases of Dercum’s disease and he did not
note explicit psychiatric manifestations in any them [11].
Moreover, severe obesity is associated with sleeping
disorders [12], which could contribute to the weakness
and susceptibility to fatigue experienced by patients with
Dercum’s disease. Previously, a clear association between
pain obesity, sleep quality and fatigue has been seen in
obese patients with fibromyalgia [13]. Furthermore,
weakness is seen in for example obese patients with sar-
copenia [14].
With regard to the fourth cardinal symptom, psychi-
atric manifestations, modern research has revealed that
pain is a common symptom in depression [15]. Similarly,
it has been demonstrated that there is a co-morbidity of
chronic pain disease and psychiatric disorders. Post-trau-
matic stress disorder (PTSD), obsessive-compulsive dis-
order (OCD), and generalised anxiety disorder (GAD)
have been expressly described in a community sample of
patients with fibromyalgia [16]. Furthermore, an
association between BMI and anxiety and personality
disorders has been seen [17]. Hence, the patients’ pain
as well as their obesity could contribute to psychiatric
Figure 2 Cumulative symptoms and signs in 110 individuals with Dercum’s disease according to a questionnaire performed by Herbst
and Asare Bediako. AD: Adiposis dolorosa, which is a synonym to Dercum’s disease. The endocrinologist, 2007 [7]. Copyright: Lippincott Williams
and Wilkins. Reprinted with permission.
Figure 1 Typical pain distribution in Dercum’s disease. Copyright: Håkan Brorson. The figure has previously been published in Läkartidningen [4].
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atic studies on the social and emotional impact of Der-
cum’s disease [18].
The four cardinal symptoms have sometimes been
used as diagnostic criteria [19-26]. However, as it is un-
clear which symptoms are cardinal and which symptoms
are minor signs in Dercum’s disease, it is unclear which
should be used as diagnostic criteria. In addition, there
are no laboratory markers for the condition and labora-
tory tests for inflammatory and autoimmune disease are
commonly negative [5,7,27-29]. Altered levels of neuro-
peptides that have been seen in different pain conditions
cannot clearly be seen in Dercum’s disease (Unpublished
observations, Hansson, Manjer, Svensson, Åberg, Fagher,
Ekman, Brorson). Based on this, we propose the ‘min-
imal definition’ based on which symptoms are most
often part of Dercum’s disease (Table 1):
1. Generalised overweight or obesity
2. Chronic pain (>3 months) in the adipose tissue
Regarding the associated symptoms in Dercum’s dis-
ease, only case reports have been published. No study
involving medical examinations has been performed in a
larger group of patients. However, Herbst and Asare-
Bediako have performed a questionnaire including 110
patients with Dercum’s disease. Common symptoms that
the patients stated included pain, fatty deposits un-
affected by weight loss, easy bruisability, sleep distur-
bances, impaired memory, depression, difficulty
concentration, anxiety, rapid heartbeat, shortness of
breath, diabetes, bloating, constipation, fatigue, weak-
ness, joint aches and muscle aches (Figure 2) [7].
Unusual signs and symptoms described
A number of other signs and symptoms have been
described in patients with Dercum’s disease. The reported
cases are summarised below.
Haddad et al. [30] reported a case of septic shock sec-
ondary to a steatocutanous necrosis in a lipoma in a pa-
tient with Dercum’s disease. The patient had a BMI ofTable 1 Classification of and diagnostic criteria for
Dercum’s disease
Classification of Dercum’s disease
I Generalised diffuse form
II Generalised nodular form
III Localised nodular form
IV Juxta-articular form
Diagnostic criteria of Dercum’s disease
1 Most often generalised overweight or obesity
2 Chronically painful adipose tissue (>3 months)46.4 kg/m2 and adipose tumours on the abdomen and on
the thighs and arms. The lipomas on the thighs had a
diameter of circa 30 cm. The necrosis, which was located
on one of the thighs, had a diameter of 15 cm and was
surrounded by an inflammatory zone of about 30 cm. The
necrosis was treated with excision and the sepsis cured
with antibiotics. The patient fulfilled the minimal criteria
for Dercum’s disease. The necrosis could be caused by a
local lymphoedema produced by strangulation of local
lymph and blood vessels, and necrosis in the lipomas is
thus truly a rare complication in Dercum’s disease.
Kyllerman et al. [31] described a family with painful
lipomatosis. The affected subjects developed associated
dysarthria, visual pursuit defects and progressive dys-
tonia. Magnetic resonance imaging revealed bilateral in-
creasing cystic lesions in the basal parts of the putamen.
No genetic abnormalities could be detected in the sub-
jects. The condition was interpreted as a Dercum’s dis-
ease variant. However, it is unclear whether the patients
truly fulfilled the criteria of Dercum’s disease. More data
are needed to determine if the cases described indeed
had a Dercum’s disease variant.
Rosenberg et al. [32] reported a case of Dercum’s dis-
ease with an unusual distribution of fatty deposits. The
adipose tissue infiltrated retroperitoneally, paravesically,
and pararectally. The disease started with painful adi-
pose tissue in the left lower extremity. Within a month
the pain had spread to the right lower extremity as well.
The same year a mass could be palpated along the right
side of the rectum. Palpation of the mass produced the
same pain in the legs as the patient had experienced
spontaneously. An intravenous pyelography and a gravity
cystogram revealed hydronephrosis bilaterally and a dis-
placed urinary bladder. A barium enema revealed an
elongated sigmoid colon displaced up-ward and to the
left. Six months later, the adipose tissue pain had spread
to both upper extremities. On examination, an irregular
mass, extending from the symphysis pubica to the um-
bilicus, could be palpated. Neurologically, a positive
Babinski’s sign was found on the left side and sensation
errors for vibration were noted at and below the iliac
crest. During surgery, an adipose tissue tumour was
found connected with the peritoneum. The tumour mea-
sured 15 by 10 cm and was adherent to the dome of the
right wall of the bladder, the right lateral rectal wall, the
right ureter and the retroperitoneal tissues. The histo-
logical examination revealed normal adipose tissue. The
condition was interpreted as Dercum’s disease, where the
adipose tissue compressed the urinary bladder, the ureter,
the sigmoid colon and the sciatic nerve. In one of the first
cases of Dercum’s disease, Dercum and McCarthy [33]
described large masses of fat in the abdomen and around
the viscera at autopsy. However, as the patient described
by Rosenberg et al. did not have any excessive painful
Figure 3 Patient with Dercum’s disease. The patient has type I Dercum’s disease, a generalised diffuse form encompassing diffusely
widespread painful adipose tissue without clear lipomas. The markings are preoperative markings before liposuction. Written informed consent
was obtained from the patient for publication of this report and any accompanying images.
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Dercum’s disease and it is hence unclear if this condition
should be classified as a separate entity. Furthermore,
contrary to in Dercum’s disease, it was not the fatty
masses themselves that were painful, but they caused
pressure on other structures and subsequent pain.
Trentin et al. [34] published a case of Dercum’s disease
where the patient developed multiple painful adipose tis-
sue lumps in the breasts. The authors concluded that
Dercum’s disease is a rare cause of mastalgia. However,
even though many women with Dercum’s disease have
painful lipomas in the breast, both idiopathic mastalgia
and lipomas are common in the breast and it is un-
decided if a single painful lipoma of the breast should
render the diagnosis Dercum’s disease. On the other
hand, it has been discussed if chronic pain syndromes,
such as fibromyalgia, might be associated with mastalgia
[35].
Reece et al. [36] noted a patient who developed painful
fatty swellings around the neck. Later, a tender lump was
excised from the back. The histological examination ofthe lump revealed normal adipose tissue. The diagnosis of
Dercum’s disease was based on the lump found on the
back. However, in Dercum’s disease, the head and neck
are not affected [4,37], even though this has recently been
contradicted by the findings of Herbst et al. [7]. Most
likely the patient described had Madelung’s disease
(Lanois-Bensaude syndrome).
Kawale et al. [38] presented a patient with Dercum’s dis-
ease who hade noticed painful thickening of the scalp in bilat-
eral parieto-occipital areas and vertex and pain while combing
for more than a year. The pain in the scalp caused headaches
and disturbed sleep and daily activities. CT and MRI revealed
diffuse thickening of the scalp tissue, but no evidence for
other anomalies. However, it is unclear what criteria were
used when making the diagnosis Dercum’s disease and hence
if the patient truly had Dercum’s disease. The findings could
be consistent with encephalocraniocutanous lipomatosis.
Szypula et al. [28] described a case of Dercum’s disease
that was affected with severe hypercholesterolemia and
advanced atherosclerosis at the age of 51. However, it is
unclear whether there is a link between Dercum’s disease
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merely represent a coexistence of two separate disorders.
Margherita [39] reported a pathological fracture in a
patient with Dercum’s disease. However, the origin of
the pathological fracture was uncertain. Furthermore, it
is uncertain if the patient fulfilled the criteria of Der-
cum’s disease.
Tsang et al. [40] noted a case of Dercum’s disease that
caused weight loss failure after Roux-en-Y gastric bypass.
Eighteen months after the operation the patient was un-
able to lose weight, despite adherence to behavioural and
dietary guidance. Endoscopy performed 15 months after
the operation excluded that any complications had oc-
curred. However, it is not stated in the article how the pa-
tient was diagnosed with Dercum’s disease and hence we
cannot evaluate if the patient truly had the disease. Der-
cum patients often report that their obesity is refractory to
diet and exercise intervention [40]. Nonetheless, this has
never been studied.
In brief, it is unclear whether some of the complications
described in Dercum’s disease are caused by the condition,
or if the occurrence of them is merely coincidental. Fur-
thermore, in a few of the described cases it is unclear if
the patients fulfilled the criteria of Dercum’s disease.
Classification
In 1900, Giudiceandrea [41] reported a patient and
reviewed all the thus far published cases. Based on the
results of the review, he proposed the following clinical
classification of Dercum’s disease:
I. Nodular type. A form with painful lipomas, most
commonly on the arms or the legs or on the back or
thorax. Sometimes the lipomas occur on multiple
locations and occasionally the lipomas form a
confluent mass. The nodules are variable in size and
painful on palpation.
II. Diffuse type. A form with diffusely painful adipose
tissue. The pain is symmetric.
III.Mixed type. A form with diffusely painful adipose
tissue and with painful nodular masses.
In 1901, Roux and Vitaut [8] modified the classifica-
tion to the following:
I. Nodular type. A form with intense pain in and
around multiple lipomas.
II. Circumscribed diffuse type. A form with painful folds
of fats. The folds are often located on the inside of
the knee and/or on the hips.
III.Generalised diffuse type. A form with diffusely
widespread painful adipose tissue. The most
common location of the pain is the extremities and
the trunk.Another classification:
I. Type I - juxta-articular
II. Type II - diffuse-generalised
III. Type III - nodular
is sometimes mentioned [4,27,42]. However, we have not
been able to establish who made this classification and
when it was compiled. The first time the term juxta-ar-
ticular Dercum’s disease was used was in 1937 by Kling
[43]. Kling reviewed 112 patients and suggested that
juxta-articular Dercum’s disease could be a precursor to
the diffuse generalised type of Dercum’s disease. Since
then, three cases of juxta-articular Dercum’s disease in
association with seropositive rheumatoid arthritis have
been reported [44,45], and Weinberger et al. [45] have
speculated on whether juxta-articular Dercum’s disease
could actually be an extra-articular manifestation of
rheumatoid arthritis. Furthermore, Kling has come up
with the theory that adipose tissue deposits around the
knees might interfere with the blood supply, by pressure
on the joint, and result in the development of painful
osteo-arthritis [43]. In brief, it is unclear whether the
juxta-articular form of Dercum’s disease exists, or if
painful localised fat around the joints simply should be
designated as the circumscribed diffuse form.
Based on our review of the literature and studies on
111 patients with Dercum’s disease [46-48] we propose
that Dercum’s disease should be classified into (Table 1):
I. Generalised diffuse form: A form with diffusely
widespread painful adipose tissue without clear
lipomas.
II. Generalised nodular form: A form with general pain
in adipose tissue and intense pain in and around
multiple lipomas.
III. Localised nodular form: A form with pain in and
around multiple lipomas
IV. Juxta-articular form: A form with solitary deposits
of excess fat for example at the medial aspect of the
knee
The suggested classification would facilitate differential
diagnosis and improve the research on Dercum’s disease.Epidemiology
Dercum’s disease most commonly appears between the
ages of 35 and 50 years [7,49]. It is five [7] to thirty
times [50] more common in women than in men and,
originally, Dercum proposed that the condition mainly
affects postmenopausal women. However, a recent
survey has revealed that 85.7 percent of the included
patients developed Dercum’s disease before menopause
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exactly established.
Aetiology
The aetiology of Dercum’s disease is unknown. However,
a number of theories for the aetiology have been sug-
gested. They are summarised below.
Endocrine dysfunction
Originally, Dercum [6] attributed the disease to an endo-
crine dysfunction, as he found atrophy of the thyroid
gland. Similarly, Waldorp [51] proposed that the disease
is caused by hypophyseal dysfunction. Furthermore,
Winkelman and Eckel [52] reviewed 16 autopsies of
patients affected with Dercum’s disease and noted vary-
ing abnormalities in different endocrine organs. In their
study, the pituitary gland was abnormal in eight of
eleven cases examined, the thyroid in twelve cases, the
sex glands in nine, the adrenal glands in three and the
pancreas in two cases.
However, endocrine involvement was doubted as early
as in 1933 [32] and further ruled out in 1952 [53]. In
addition, present-day methods have not revealed any
endocrine abnormalities [19,22,42,54,55]. For example,
Piementa et al. [54] have demonstrated that hormonal
secretion was normal both basally and during a 24 h
period in a patient with Dercum’s disease, and no hor-
monal deficiency could be detected after an integrated
pituitary stimulus test. The study suggested that there
probably are no alterations of the endocrine glands, as
regards the pituitary gland, the adrenal glands, the thy-
roid and the ovaries, in patients with Dercum’s disease.
In another study, a paradoxical increase in growth hor-
mone was seen after an intravenous injection of thyrop-
tropin [56]. The significance of this finding is unclear. In
brief, an endocrine dysfunction as the aetiology of Der-
cum’s disease has little support in the modern literature.
Nervous system dysfunction
Dalziel [57] suggested that the autonomous nervous
system mediates pain in Dercum’s disease. The the-
ory is supported in that, even though the sympa-
thetic nervous system is efferent, sympathectomy
sometimes relieves neuropathic pain, where evidence
of damage to neural structures exists [58]. This has
been explained by the formation of abnormal con-
nections between autonomic and sensory nerves in
the periphery and, as a consequence, abnormal auto-
nomic signalling to the spinal column that might ac-
tivate pain fibres [57]. However, in conditions where
neural damage cannot be found, the effect on pain
might be caused by the placebo response [59]. More-
over, patients with Dercum’s disease could have
increased sympathetic activity induced by pain. Thistheory is supported by a study where a patient with
Dercum’s disease did not have any vasoconstrictor
response to arm and leg lowering. A normalised
vasoconstrictor response could be created by lido-
caine infusion that is thought to decrease the local
or central sympathetic vasoconstrictor tone [60].
Furthermore, visceral pain may be generated by the
autonomic nervous system, and factors that induce vis-
ceral pain could also have the ability to induce pain in
the adipose tissue. Examples of such factors are anoxe-
mia, formation and accumulation of pain-producing
substances, traction or compression of vessels, inflam-
matory states, and necrosis [57]. Nonetheless, any sub-
stantial evidence of nervous system dysfunction has
never been found in Dercum’s disease and is hence
merely a theory.
Mechanical pressure on the nerves
Pain has been suggested to arise from the stretching of
and pressure on nerves by growing fatty masses [23,61].
However, this theory has never been confirmed
histopathologically.
Adipose tissue dysfunction
Another aetiology that has been proposed for Dercum’s
disease is a local defect in lipid metabolism [19]. An in-
vestigation [19] of fatty acid biosynthesis in two patients
with Dercum’s disease suggested that there might be a
deficit in the formation of mono-unsaturated fatty acids
in subjects affected by the disease. In one of these cases,
there was a discrepancy in the formation of long-chain
mono-unsaturated fatty acids (16:1 and 18:1) (fatty acids
are denoted as number of carbon atoms:number of
double bonds) in painful adipose tissue, whereas the for-
mation in the unaffected adipose tissue was normal. In
the other case, synthesis of 16:1 fatty acids was detected;
on the other hand, the synthesis of 18:1 fatty acids
seemed to be completely blocked in painful adipose tis-
sue. However, contradictory findings were revealed in
another study, comprised of 13 patients with Dercum’s
disease [62]. This investigation showed that the propor-
tion of monounsaturated fatty acids (16:1 and 18:1) was
significantly higher in the patients with Dercum’s disease
than in the healthy controls. On the other hand, the pro-
portions of saturated (14:0 and 18:0) and some other un-
saturated fatty acids (18:3 and 20:1) were increased.
Another finding that supports a local defect in lipid
metabolism is corticosteroid-induced juxta-articular
Dercum’s disease [63]. A causal relationship between
corticosteroids and Dercum’s disease was suggested as
the symptoms of Dercum’s disease developed in one case
when the patient was temporarily treated with high-dose
corticosteroids; the symptoms later resolved when the
dosage was reduced. The authors suggested that the
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caused the temporary onset of Dercum’s disease.
Pimenta et al. performed an in vitro study on normal
and painful fat from a patient with Dercum’s disease.
The study revealed that the painful adipose tissue had
reduced responsiveness to norepinephrine and a lack of
response to the anti-lipolytic effect of insulin compared
to non-painful adipose tissue [54]. In another in vitro
study, a sample of painful adipose tissue from a subject
affected with Dercum’s disease converted glucose to
neutral glycerides at a significantly lower rate than non-
painful adipose tissue from the same subject [56].
In addition, one of the studies [62] also revealed that
patients with Dercum’s disease have significantly higher
fat-cell heat production, compared to obese healthy con-
trols, expressed in μW/g, as well as in pW/cell. The
authors speculated on whether this could be explained
by higher sympathetic activity due to nociceptive stimuli
in the painful adipose tissue. However, one patient in the
study had unilateral disease, and adipose cells from the
painful side demonstrated lower heat production than
cells from the pain-free side. Furthermore, a study [64]
performed on 10 patients with Dercum’s disease con-
cluded that women with Dercum’s disease have lower
resting energy expenditure on the basis of total body
mass (kg) than healthy controls. The relevance of these
findings is unclear.
In conclusion, as regards adipose tissue function in
Dercum’s disease, the findings are inconclusive and the
pathophysiological and clinical significance of the find-
ings are unclear.
Inflammation
An inflammatory aetiology has been proposed for Der-
cum’s disease [4,28,65]. However, laboratory markers for
inflammation markers, such as erythrocyte sedimenta-
tion rate (ESR) and C-reactive protein (CRP), are usually
normal in the condition [5,7,19,27-29,39,42,44,50,63,66-
68]. However, a few studies have revealed that some
patients have elevated levels of CRP and ESR. In A study
from 1937, including 112 females, reported that 66% of
the patients with Dercum’s disease have been observed
to have ESR>15 [43]. A study by Herbst and Asare-
Bediako [7], 33% of the patients with Dercum’s disease
had elevated CRP levels and 38% had elevated ESR
levels. However, 38% of the patients included in the
study had autoimmune disease, such as rheumatoid
arthritis and lupus Furthermore, markers for auto-
immune disease, such as rheumatoid factor (RF), anti-
nuclear antibodies (ANA), anticardiolipin antibodies
(ACA), perinuclear anti-neutrophil cytoplasmic anti-
bodies (pANCA), cytoplasmic anti-neutrophil cytoplas-
mic antibodies (cANCA) and antibodies against native
DNA, are commonly negative in Dercum’s disease[5,27,28,44]. In the study by Herbst and Asare-
Bediako [7], 31% of the patients had positive titres
for ANA. However, it is unclear if these patients
were among the 38% that had an autoimmune
disease.
A study on adipokines in Dercum’s disease has indicated
that there is no difference in the levels of tumour necrosis
factor (TNF)-α, leptin, adiponectin, plasminogen activator
inhibitor-1, interleukin (IL)-1β, IL-8, IL-10, macrophage in-
flammatory protein (MIP)-1α, and monocyte chemotactic
protein (MCP) compared to controls. Nonetheless, signifi-
cantly lower MIP-1β expression [64] and a trend toward
higher levels of IL-13 and lower levels of fractalkine were
seen. The authors concluded that the lowered fractalkine
levels were logical, since with prolonged release of fractalk-
ine as seen in neuropathic pain, the receptors to which
fractalkine binds are upregulated. This suggests that there
is shift from fractalkine release to receptor-bound fractalk-
ine. The lower levels of fractalkine found in Dercum’s dis-
ease could thus suggest that the substance is receptor-
bound. When receptors are occupied by fractalkine, pain
and resistance to opioid analgesia are promoted. This is in
accordance with the symptoms in Dercum’s disease [64]. A
recent investigation of inflammatory signs in adipose tissue
of Dercum patients suggests that there is an inflammatory
response. However, this response is not more pronounced
than that in healthy obese controls. This contradicts inflam-
mation as the aetiology of Dercum’s disease [47].
In brief, there are no uniform findings pointing to an
inflammatory aetiology in Dercum’s disease.
Trauma-induced Dercum’s disease
Two cases of trauma-induced [39,69] Dercum’s disease
have been described. The first patient developed a painful
fatty tumour, which was very sensitive to pressure and
gave rise to much spontaneous pain, after falling on a
stone pavement. The painful adipose tissue lingered for a
year after the disappearance of the bruises [69]. In the
second case, the patient fell down a tree and landed on
his right shoulder one year before the onset of Dercum’s
disease. No fracture could be detected. One year after the
accident, a painful adipose tissue tumour started to grow
on his right shoulder. Five years after the injury, an x-ray
of the painful shoulder was performed and a humeral
fracture that appeared pathological was found. However,
the origin of the pathological fracture is unclear [39].
All in all, cases of trauma induced Dercum’s disease
seem to occur. However, in some of the cases reported
in the literature the evidence is circumstantial.
Diagnosis (diagnostic criteria and algorithms) and
diagnostic methods
The basic diagnostic criteria for Dercum’s disease are
(Table 1):
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2. Chronic pain (>3 months) in the adipose tissue
Diagnosis should be made by systematic physical
examination and thorough exclusion of differential diag-
noses. Advisably, the diagnosis should be made by a
physician with a broad experience of patients with pain-
ful conditions and knowledge of family medicine, in-
ternal medicine or algology. The diagnosis should only
be made when the differential diagnoses have been
excluded [70].
Based on our clinical experience and review of the lit-
erature we propose the following additional guidelines
for diagnosis: Patients who have painful generalised
overweight or obesity of the lower extremities should
only be diagnosed as lipoedema. If there are isolated
painful lipomas or accumulations of fat, the patient
should be diagnosed with nodular Dercum’s disease. In
cases where the patient fulfils the criteria for fibromyal-
gia they should primarily be diagnosed with fibromyal-
gia. Only if the patient also has lipomas should he or she
be diagnosed with Dercum’s disease as well. Patients
who only have excess fat accumulation in the head, neck
region, and upper torso should be diagnosed with Made-
lung’s disease (Lanois-Bensaude syndrome).
Differential diagnoses
Many diagnoses have similar symptoms as the symptoms
experienced in Dercum’s disease. The diffuse types of





Endocrine disorders encompassing obesity and pain, e.
g. Cushing’s syndrome and hypothyroidism
Primary psychiatric conditions encompassing pain, e.g.
depression. Especially in combination with obesity.
The nodular type of Dercum’s disease has to be differ-
entiated from conditions that may include lipomas or
solitary deposits of excess fat that are sometimes painful:




Multiple endocrine neoplasia I (MEN I)
Myoclonic epilepsy with red ragged fibres (MERRF)
Familial multiple lipomatosis
The similarities and differences of these conditions
and Dercum’s disease are briefly presented below.Fibromyalgia is a condition with widespread muscle
pain and a painful response to pressure on at least 11
out of 18 specific tender point sites. It is associated with
a range of other symptoms, such as sleep disturbances,
fatigue, cognitive disturbances, and depressive symptoms
[71]. The aetiology is unknown [75,76] and the demarca-
tion from Dercum’s disease is sometimes arbitrary, espe-
cially in cases when the patient is obese.
Lipoedema is characterised by bilateral, symmetric
lower extremity enlargement due to subcutaneous depos-
ition of adipose tissue. The patients experience pain on
palpation. The condition affects women almost exclu-
sively. Typically, the disorder develops insidiously after
puberty and progresses gradually. Moreover, patients
with morbid obesity and longstanding lipoedema can de-
velop a secondary mechanical insufficiency of the lymph-
atic system, producing a lipolymphoedema [72] due to
associated difficulties with ambulation, which limits acti-
vation of the muscle pump in the lower extremities and
subsequently leads to pitting oedema due to inactivity
[73].
Panniculitis is a group of inflammatory conditions in
which the principal focus is the subcutis. The condition
encompasses painful subcutaneous masses and is there-
fore a possible differential diagnosis to Dercum’s disease.
Panniculitis is classified according to which structure it
affects: septal panniculitis denotes inflammation in the
connective tissue septa, whereas lobular panniculitis refers
to inflammation in the fat lobules. Panniculits occurs with
or without accompanying vasculitis. Septal panniculitis
without vasculitis (erythema nodosum) most commonly
manifests itself as tender erythematous nodules on the
lower extremity. As some nodules heal, others arise. Nor-
mally, all lesions heal without scarring within six weeks.
Lobular panniculitis with vasculitis (erythema induratum,
nodular vasculitis) presents itself with recurrent, tender,
erythematous subcutaneous nodules on the lower extrem-
ity. The lesions frequently ulcerate, and they heal with
atrophic scars. The condition may continue for several
years. A special form of panniculitis is Pfeifer-Weber-
Christian disease (idiopathic relapsing febrile lobular non-
suppurative panniculitis)[74].
A number of endocrine disorders can cause generalised
pain in combination with obesity and psychiatric symp-
toms. For example, Cushing’s syndrome (corticotropin-in-
dependent adrenal hyperfunction) is characterised by
aching joints, as well as a gradual onset of obesity, typically
located around the face (‘moon face’), back (‘buffalo hump’),
and trunk. In addition, the majority of patients suffer from
psychiatric manifestations, including irritability, emotional
labiality, and depression [75]. Another endocrine disorder,
encompassing weight gain and pain in the extremities, is
hypothyroidism. If myxoedema develops, oedema of the
face, hands and feet are added to the signs [75]. Usually, the
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pose tissue.
Lipodystrophies are characterised by selective loss of
body fat from different parts of the body. The adipose tis-
sue loss can be limited, and result in well-demarked sub-
cutaneous areas, or extensive, leading to widespread
absence of body fat [77]. There are different types of lipo-
dystrophies, both congenital forms, such as Berardinelli-
Seip syndrome, and acquired forms, such as Lawrence
syndrome and Barraquer-Simons syndrome [78]. On the
other hand, localised excess deposition of fat is also a lipo-
dystrophy and comprise most patients that have liposuc-
tion for cosmetic reasons. Furthermore, patients who have
no pain and with lipoedema-like distribution of fat also
belong to the lipodystrophies.
Patients with depression are often diagnosed with
chronic pain conditions and vice versa [79]. Both disor-
ders activate common neurocircuitries, for example, the
hypothalamic-pituitary-adrenal axis, limbic and paralim-
bic structures, ascending and descending pain pathways
[80], and it is therefore sometimes difficult to determine
whether the pain disorder or the psychiatric condition is
the primary diagnosis.
Multiple symmetric lipomatosis is principally distin-
guished by large subcutaneous fatty masses distributed in a
symmetrical fashion around the neck, shoulders, upper ex-
tremities, trunk, and sometimes intrathoracic. Epidemiolo-
gically, the incidence of the disorder is highest in males and
is often associated with alcoholism. The majority of the
patients are not obese. The fat accumulations are usually
not experienced as painful [81]. Sometimes multiple lipo-
matosis is inherited in an autosomal-dominant way, and is
then referred to as familial multiple lipomatosis. The condi-
tion can be associated with an A to G mutation at position
A8344 of mitochondrial DNA [82]. The fatty masses in
multiple symmetric lipomatosis are not painful and it is
hence possible to differentiate from Dercum’s disease. Mul-
tiple symmetric lipomatosis is a separate entity from famil-
ial multiple lipomatosis.
Some patients with neurofibromatosis type 1 (von
Recklinghausen’s disease) develop subcutaneous neuro-
fibromas that cause pain and neurological symptoms
[83]. Neurofibromas are pathohistologically distinct from
lipomas.
Benign adipose tissue tumours (solitary/multiple) are sub-
cutaneous tumours composed of well-differentiated adipo-
cytes. There are a number of varieties of lipomas, some of
which are frequently painful [75]. Malignant cutaneous adi-
pose tissue neoplasms are exceptionally rare and are usually
not experienced as painful. Such tumours include cutane-
ous angiolipoleiomyoma (‘angiomyolipoma’), adenolipoma
of the skin, cutaneous spindle cell/pleomorphic lipomas,
and liposarcomas [84]. Tumours are normally easily differ-
entiated from Dercum’s disease, as they are not painful.Patients with multiple endocrine neoplasia I (MEN 1)
sometimes exhibit several subcutaneous tumours, in-
cluding multiple lipomas, which are, however, not pain-
ful [85]. MEN 1 is easily differentiated from Dercum’s
disease as the lipomas in MEN 1 are not painful.
Myoclonic epilepsy with ragged red fibres (MERRF),
an inherited disease of the mitochondria, is sometimes
accompanied by multiple symmetric lipomatosis. The
most common cause is a mutation in position 8344 of
the tRNA gene of mitochondrial DNA [86]. MERRF is
easily differentiated from Dercum’s disease, as the lip-
omas in MERRF are not painful.
In conclusion, the differential diagnosis is a challenge
principally in cases where diffuse Dercum’s disease is one
of the tentative diagnoses. All differential diagnoses have
to be excluded before Dercum’s disease can be diagnosed.Genetic counselling
The majority of the cases of Dercum’s disease occur spor-
adically. We have found five reports on the inheritance of
the disorder. The studies have suggested that Dercum’s
disease might be an autosomal dominant disorder with
variable expression [18,49,87-89]. A gender factor has
been proposed as the affected women were markedly
obese and experienced considerable pain, whereas the ex-
pression of the disease in the affected men was so mild
that it would not have been noticed if a very thorough
physical examination had not been performed [88]. The
possible genetic heterogeneity could explain why the dis-
ease has been reported in females with a frequency that is
up to 30 times greater than in males [50]. Furthermore, it
has been suggested that some cases of Dercum’s disease
might actually be an extreme expression of familial mul-
tiple lipomas [31,87]. This implies that some of the
affected men could have been given the diagnosis familial
multiple lipomas instead of Dercum’s disease, as their
symptoms are so discreet [49].
In addition, studies have revealed that the A to G mu-
tation at position A8344 of mitochondrial DNA, which
is sometimes associated with familial multiple lipomas,
cannot be detected in patients with Dercum’s disease
[31,87]. Similarly, HLA (human leukocyte antigen) typ-
ing, which has been performed in a family of five
patients affected by Dercum’s disease [54], has not
revealed any correlation between typical antigens and
the presence of the condition.Management including treatment
Few convincing large studies on the treatment of Der-
cum’s disease have been conducted. Most of the different
treatment strategies that exist are based on case reports.
The described treatments are summarised below.
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A number of patients treated with liposuction have been
presented [46,70]. In all cases, suction-assisted liposuc-
tion was used. The ‘dry’ technique was applied by all
investigators, with the exception of one, who used the
tumescence technique with 0.1 percent prilocarpine so-
lution. The mechanism behind pain relief following lipo-
suction is thought to be that nerve plexuses in the
adipose tissue are destroyed [57]. However, it is unlikely
that direct nerve destruction alone explains the pain re-
duction seen following liposuction [48]. Furthermore,
the reduction in pain in Dercum’s disease persisted
longer than sensitivity loss normally seems to persist
after liposuction in healthy patients [46].
Lipectomy has been tried in a few cases
[23,25,43,50,61,67,90,91]. The treatment was effective,
but the pain returned in all cases but one.
Traditional analgesics
The pain in Dercum’s disease is often refractory to
analgesics and to non-steroidal anti-inflammatory drugs
(NSAIDs) [44,56,67,68,92-98]. However, this has recently
been contradicted by the findings of Herbst et al. [7].
They reported that the pain diminished in 89% of
patients (n=89) when treated with NSAIDs and in 97%
of patients when treated with narcotic analgesics (n=37).
Nonetheless, the dosage required and the duration of
the pain relief were not precisely stated in the article.
Lidocaine
An early report from 1934 showed that intralesional
injections of procaine (NovocainW) relieved pain in six
cases [99]. More recently, other types of local treatment
of painful sites with lidocaine patches (5%) (LidodermW)
[29,100] or lidocaine/prilocaine (25 mg/25 mg) cream
(EMLAW) [101] have shown a reduction of pain in a few
cases.
In the 1980s, treatment with intravenous infusions of
lidocaine (XylocaineW) in varying doses was reported in
nine patients [21,22,27,56,60,92,97,102]. The resulting
pain relief lasted from 10 hours [21] to 12 months [92].
In five of the cases, the lidocaine treatment was com-
bined with mexiletine (MexitilW), which is a class 1B
anti-arrhythmic with similar pharmacological properties
as lidocaine [27,36,42,102].
The mechanism by which lidocaine reduces pain in
Dercum’s disease is unclear. It may block impulse con-
duction in peripheral nerves [21], and thereby disconnect
abnormal nervous impulse circuits [102]. Nonetheless, it
might also depress cerebral activity that could lead to
increased pain thresholds [21]. Iwane et al. [21] per-
formed an EEG during the administration of intravenous
lidocaine. The EEG showed slow waves appearing 7 min-
utes after the start of the infusion and disappearingwithin 20 minutes after the end of the infusion. On the
other hand, the pain relief effect was the greatest at about
20 minutes after the end of the infusion. Based on this,
the authors concluded that the effect of lidocaine on per-
ipheral nerves most likely explains why the drug has an
effect on pain in Dercum’s disease. In contrast, Atkinson
et al. [92] have suggested that an effect on the central
nervous system is more likely, as lidocaine can depress
consciousness and decrease cerebral metabolism [92]. In
addition, Skagen et al. [60] demonstrated that a patient
with Dercum’s disease lacked the vasoconstrictor re-
sponse to arm and leg lowering, which indicated that the
sympathicus-mediated local veno-arteriolar reflex was
absent. This could suggest increased sympathetic activity.
An infusion of lidocaine increased blood flow in subcuta-
neous tissue and normalised the vasoconstrictor response
when the limbs were lowered. The authors suggested that
the pain relief was caused by a normalisation of up-regu-
lated sympathetic activity.
Methotrexate and infliximab
One patient’s symptoms were improved with methotrex-
ate and infliximab (RemicadeW) [103]. However, in an-
other patient with Dercum’s disease, the effect of
methotrexate was discreet [18]. The mechanism of ac-
tion is unclear. Previously, methotrexate has been shown
to reduce neuropathic pain caused by peripheral nerve
injury in a study on rats [104].
The mechanism in the rat study case was thought to
be a decrease in microglial activation subsequent to
nerve injury [104]. Furthermore, a study has shown that
infliximab reduces neuropathic pain in patients with
central nervous system sarcoidosis. The mechanism is
thought to be mediated by tumour necrosis factor inhib-
ition [105].
Interferon α-2b
Two patients were successfully treated with interferon
α-2b [106]. The authors speculated on whether the
mechanism could be the antiviral effect of the drug, the
production of endogenous substances, such as endor-
phins, or interference with the production of interleu-
kin-1 and tumour necrosis factor. Interleukin-1 and
tumour necrosis factor are involved in cutaneous
hyperalgesia.
Corticosteroids
A few patients noted some improvement when treated
with systemic corticosteroids (prednisolone) [55,93,107],
whereas others experienced worsening of the pain [63].
Weinberg et al. [45] treated two patients with juxta-articu-
lar Dercum’s disease with intralesional injections of
methylprednisolone (Depo-MedrolW). The patients experi-
enced a dramatic improvement.
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costeroids in some conditions is unknown. One theory
is that they inhibit the effects of substances, such as his-
tamine, serotonin, bradykinin, and prostaglandins [108].
As the aetiology of Dercum’s disease is probably not in-
flammatory, it is plausible that the improvement some
of the patients experience when using corticosteroids is
not caused by an anti-inflammatory effect.
Calcium-channel modulators
Several calcium-channel modulators have been tried; for
instance, pregabalin (LyricaW) (anticonvulsant) [5] and
oxacarbazepine (TrileptalW) (anticonvulsant) [42,66,109].
Calcium-channel modulators inhibit the activation of
neuronal calcium channels and thereby inhibit the release
of substances, such as excitatory amino acids, that are ne-
cessary for central sensitisation. These drugs are used to
treat neuropathic pain [110]. Several of these substances
have a broad range of pharmacological actions and other
mechanisms beyond calcium-channel modulation that
might contribute to their effectiveness in treating neuro-
pathic pain [110].
D-thyroxine
D-thyroxine (LevaxineW) has not given any symptomatic
relief in Dercum’s disease [62]. This further supports
that the thyroid gland is not involved in the pathogenesis
of the disease.
Rapid cycling hypobaric pressure
A pilot study [111], including 10 patients, has suggested
that rapid cycling hypobaric pressure might decrease
pain patients with Dercum’s disease. Different mechan-
isms have been proposed for the effect: pneumatic dis-
placement of fluid, that is, a decrease in tissue oedema,
improved blood flow through intermittent compression
and an increase in arterial oxygen saturation and an de-
crease in hypoxia in the painful tissue [111].
Prognosis
There has been little research conducted on the natural
history of Dercum’s disease, but case reports have sug-
gested that the pain might be aggravated over time [18].
However, this is not clearly supported in a recent study
with a five year follow-up. In that study, the average pain
was relatively constant over five years (about 5/10 on a
visual analogue scale). On an individual level some
patients experienced less pain after five years and some
more [46].
Unresolved questions
The diagnostic criteria for Dercum’s disease have never
been validated. The Classification and Response Criteria
Sub-committee, supported by the American College ofRheumatology, have developed recommendations for the
development and validation of criteria sets [112]. Accord-
ing to these recommendations, criteria should be devel-
oped using appropriate consensus methodology, and all of
the criteria should be reliable, that is, they should be stable
when there is no clinical change, precise in their measure-
ment, easy to measure and clinically sensible, and differen-
tiate the condition from other conditions[112]. Further
work is needed to validate the diagnostic criteria of Der-
cum’s disease, according to the recommendations of the
American College of Rheumatology.
The prevalence of Dercum’s disease has not yet been
exactly established and the prognosis is described differ-
ently in different reports.
The aetiology of Dercum’s disease is unknown. Syn-
dromes with unclear aetiology and no objectively ob-
servable abnormalities are sometimes refereed to as
functional somatic syndromes and include, for example,
irritable bowel syndrome, non-ulcer dyspepsia, premen-
strual syndrome, chronic pelvic pain, fibromyalgia,
chronic fatigue syndrome, tension headaches, temporo-
mandibuar joint dysfunction, globus syndrome and mul-
tiple chemical sensitivity. These syndromes often affect
females, are negatively affected by stress, demonstrate
co-existing emotional disorders, have a similar prognosis
and respond to different treatments in a similar way
[113]. At least diffuse Dercum’s disease may qualify as a
functional somatic syndrome, as it overlaps with some of
the above mentioned conditions and patients with Der-
cum’s disease often meet diagnostic criteria for one or
several of the functional somatic syndromes. Patients
with Dercum’s disease and functional somatic syndromes
share non-symptomatic characteristics, that is, they are
predominantly women, they often have emotional disor-
ders and difficulties in doctor-patient relationship [113].
This suggests that more general strategies should be
developed for the management of Dercum’s disease. Pres-
ently, patients in these domains of disease are probably
best treated by more general strategies in multidisciplinary
teams specialised in chronic pain [113]. Furthermore, this
kind of treatment has been used successfully in patients
with for example fibromyalgia [114].
Conclusion
The diagnostic criteria of Dercum’s disease are proposed
to be generalised overweight or obesity and painful adi-
pose tissue. However, the diagnostic criteria need to be
validated. The disease is preferably classified as: I. Gener-
alized diffuse form - a form with diffusely widespread
painful adipose tissue, II. General nodular form - a form
with general and intense pain in and around multiple
lipomas, III. Localized nodular form - a form with pain
in and around multiple lipomas, and IV. Juxta-articular
form - a form with solitary deposits of excess fat for
Hansson et al. Orphanet Journal of Rare Diseases 2012, 7:23 Page 13 of 15
http://www.ojrd.com/content/7/1/23example at the medial aspect of the knee. The aetiology of
Dercum’s disease is unknown and there is hence no good
treatment available. Presently, patients with Dercum’s dis-
ease are probably best treated by more general strategies
in multidisciplinary teams specialised in chronic pain. This
kind of treatment has been used successfully in patients
with for example fibromyalgia.
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